deltatrials
Completed PHASE1 NCT00024557

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

Phase I Study to Assess the Histologic Effect and Safety of Pre-Operative and Post-Operative Infusions of IL13-PE38QQR Cytotoxin in Patients With Recurrent Resectable Supratentorial Malignant Glioma

Sponsor: INSYS Therapeutics Inc

Conditions Anaplastic Astrocytoma Glioblastoma Multiforme Malignant Astrocytoma Malignant Glioma Mixed Oligoastrocytoma
Interventions IL13-PE38QQR surgery targeted fusion protein therapy
Updated 5 times since 2017 Last updated: Jun 2, 2011 Started: Jun 30, 2001 Primary completion: Jun 30, 2006 Completion: Jul 31, 2007

Listed as NCT00024557, this PHASE1 trial focuses on Anaplastic Astrocytoma and Glioblastoma Multiforme and remains completed. Sponsored by INSYS Therapeutics Inc, it has been updated 5 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Jun 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • INSYS Therapeutics Inc
Data source: INSYS Therapeutics Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Houston, United States
  • • New Haven, United States
  • • New York, United States
  • • San Francisco, United States